Literature DB >> 32530350

The synthetic cannabinoids phenomenon: from structure to toxicological properties. A review.

Vera L Alves1, João L Gonçalves1, Joselin Aguiar1, Helena M Teixeira2,3, José S Câmara1,4.   

Abstract

The word "cannabinoid" refers to every chemical substance, regardless of structure or origin, that joins the cannabinoid receptors of the body and brain and that have similar effects to those produced by the Cannabis plant and based on their source of production, cannabinoids can be classified into endocannabinoids, phytocannabinoids and synthetic cannabinoids. Synthetic cannabinoids represent the largest class of drugs detected through the EU Early Warning System with a total of 190 substances notified from 2008 to 2018 and about 280 have been reported worldwide to the United Nations Office on Drugs and Crime. Sprayed on natural herb mixtures with the aim to mimic the euphoria effect of cannabis and sold as "herbal smoking blends" or "herbal incense" under brand names like "Spice" or "K2", synthetic cannabinoids are available from websites for the combination with herbal materials or more recently, for the use in e-cigarettes. Currently labeled as "not for human consumption" to circumvent legislation, their legal status varies by country with many government institutions currently pushing for their control. However, due to the emergence of new substances, it requires a constant update of the list of controlled drugs. Little is known about how these substances work and their toxic effects in humans and the same product could vary not only in the amount and in the type of substance added. In the last years, synthetic cannabinoids have been associated with deaths and acute intoxications in Europe and, despite a range of new measures introduced in this area, continue to represent a challenge to current drug policy models. These synthetic substances are much more potent than natural cannabis, as well as displayed greater efficacy, acting as full agonists at the cannabinoid receptors. It is possible that, along with being highly potent, some may also have long half-lives, potentially leading to a prolonged psychoactive effect. The present work provides a review on existing literature about the development of synthetic cannabinoids as substances of abuse, current patterns of abuse and their legal status, chemical classification, and some pharmacological and toxicological properties.

Entities:  

Keywords:  Synthetic cannabinoids; cannabis; new psychoactive substances; pharmacology; toxicology

Year:  2020        PMID: 32530350     DOI: 10.1080/10408444.2020.1762539

Source DB:  PubMed          Journal:  Crit Rev Toxicol        ISSN: 1040-8444            Impact factor:   5.635


  12 in total

Review 1.  The why behind the high: determinants of neurocognition during acute cannabis exposure.

Authors:  Johannes G Ramaekers; Natasha L Mason; Lilian Kloft; Eef L Theunissen
Journal:  Nat Rev Neurosci       Date:  2021-05-27       Impact factor: 34.870

Review 2.  Detection of the Synthetic Cannabinoids AB-CHMINACA, ADB-CHMINACA, MDMB-CHMICA, and 5F-MDMB-PINACA in Biological Matrices: A Systematic Review.

Authors:  Elisabet Navarro-Tapia; Jana Codina; Víctor José Villanueva-Blasco; Óscar García-Algar; Vicente Andreu-Fernández
Journal:  Biology (Basel)       Date:  2022-05-23

Review 3.  Targeting the Endocannabinoidome in Pancreatic Cancer.

Authors:  Valerio Falasca; Marco Falasca
Journal:  Biomolecules       Date:  2022-02-17

4.  Determination of the Synthetic Cannabinoids JWH-122, JWH-210, UR-144 in Oral Fluid of Consumers by GC-MS and Quantification of Parent Compounds and Metabolites by UHPLC-MS/MS.

Authors:  Nunzia La Maida; Manuela Pellegrini; Esther Papaseit; Clara Pérez-Mañá; Lourdes Poyatos; Mireia Ventura; Liliana Galindo; Francesco Paolo Busardò; Simona Pichini; Magí Farré; Emilia Marchei
Journal:  Int J Mol Sci       Date:  2020-12-10       Impact factor: 5.923

Review 5.  Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses.

Authors:  Kenneth B Walsh; Amanda E McKinney; Andrea E Holmes
Journal:  Front Pharmacol       Date:  2021-11-29       Impact factor: 5.810

6.  Shifting North American drug markets and challenges for the system of care.

Authors:  R Michael Krausz; Jean N Westenberg; Nickie Mathew; George Budd; James S H Wong; Vivian W L Tsang; Marc Vogel; Conor King; Vijay Seethapathy; Kerry Jang; Fiona Choi
Journal:  Int J Ment Health Syst       Date:  2021-12-20

7.  Synthetic cannabinoids use in a sample of opioid-use disorder patients.

Authors:  María Alías-Ferri; Manuela Pellegrini; Emilia Marchei; Roberta Pacifici; Maria Concetta Rotolo; Simona Pichini; Clara Pérez-Mañá; Esther Papaseit; Robert Muga; Francina Fonseca; Magi Farré; Marta Torrens
Journal:  Front Psychiatry       Date:  2022-08-03       Impact factor: 5.435

Review 8.  Cannabinoids and PPAR Ligands: The Future in Treatment of Polycystic Ovary Syndrome Women with Obesity and Reduced Fertility.

Authors:  Piotr Przybycień; Danuta Gąsior-Perczak; Wojciech Placha
Journal:  Cells       Date:  2022-08-18       Impact factor: 7.666

9.  Molecular signaling of synthetic cannabinoids: Comparison of CB1 receptor and TRPV1 channel activation.

Authors:  Haley K Andersen; Kenneth B Walsh
Journal:  Eur J Pharmacol       Date:  2021-07-02       Impact factor: 5.195

Review 10.  Cannabinoid Signalling in Immune-Reproductive Crosstalk during Human Pregnancy.

Authors:  Harmeet Gurm; Jeremy A Hirota; Sandeep Raha
Journal:  Biomedicines       Date:  2021-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.